glp3.wiki

Dr. Alex Tatem on Retatrutide: A Physician's Breakdown Fact-Checked

Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

Board-certified urologist Dr. Alex Tatem published a September 29, 2025 video titled "Doctor Explains Retatrutide: The Most Powerful GLP-1 Weight Loss Drug Yet" covering the mechanism of action, Phase 2 trial data, comparison to semaglutide and tirzepatide, side effects, and FDA approval timeline. As a fellowship-trained physician and men's health specialist, Tatem brings medical credibility to the discussion — though his specialty is urology, not endocrinology or obesity medicine.
This page checks the retrieved video transcript against published data and separates his September 2025 account from later trial results. Tatem does not recommend grey market retatrutide and explicitly warns against unregulated sourcing.
Go to the source: Original video, mechanism at 4:25, Phase 2 results at 7:58, drug comparisons at 8:28, and side effects at 11:00.

The Triple Agonist Mechanism: Human Evidence vs Theory

Tatem provides a clear explanation of the three receptors retatrutide targets and what each does:

"Retatrutide enters the chat as the world's first triple agonist GLP-1 drug targeting GLP-1, GIP, and the glucagon receptor itself... This burn-a-bit-more component is likely why we see a steeper early weight loss curve with retatrutide compared to its competition."

— Dr. Alex Tatem

He correctly identifies GLP-1, GIP and glucagon receptor agonism. The claim about greater energy expenditure needs qualification: the early retatrutide study demonstrated this in mice and said translation to humans required further study. Receptor activity alone does not establish how much of human weight loss comes from increased calorie burning.

The Phase 2 liver substudy reported higher beta-hydroxybutyrate concentrations, consistent with altered fat metabolism. It did not directly compare retatrutide with a matched calorie-restriction program or prove superiority to dieting.

For the full mechanism explanation, see What Is Retatrutide. For the fatty liver data, see Retatrutide and Fatty Liver.

Phase 2 Weight Loss Data: Accurate

Tatem cites specific Phase 2 numbers:

"Patients on 8 milligrams a week experienced a mean weight change of 22.8% and patients on 12 milligrams experienced a 24.2% reduction."

— Dr. Alex Tatem

ClaimPublished NEJM DataVerdict
8mg: 22.8% weight loss at 48 weeks-22.8% (pooled 8mg group)Accurate
12mg: 24.2% reduction at 48 weeks-24.2% at 12mgAccurate
100% of max-dose patients lost at least 5%100% at 12mg lost ≥5%Accurate
93% lost at least 10%93% at 12mg lost ≥10%Accurate
83% lost over 15%83% at 12mg lost ≥15%Accurate
By 24 weeks: 17.3–17.5% loss at top doses~17% at 24 weeks for 8–12mg groupsAccurate
The main weight-loss figures match the Phase 2 paper. The 83% threshold is at least 15%, rather than strictly over 15%. The pooled 8 mg and 12 mg groups lost 17.3% and 17.5% at week 24. Those findings do not establish that retatrutide acts faster than another drug tested in a different trial.
For the full trial data, see Retatrutide Results.

Drug Comparisons: Accurate and Well-Contextualized

Tatem compares retatrutide's Phase 2 results to published data from semaglutide and tirzepatide:

Swipe sideways to see every column.

DrugHis ClaimPublished DataVerdict
Semaglutide (STEP 1)14.9% at 68 weeks (2.4mg dose)14.9% at 68 weeksAccurate
Tirzepatide 5mg (SURMOUNT-1)15% at 72 weeks15.0% at 72 weeksAccurate
Tirzepatide 10mg19.5% at 72 weeks19.5% at 72 weeksAccurate
Tirzepatide 15mg20.9% at 72 weeks20.9% at 72 weeksAccurate
HbA1c reduction (retatrutide)2 points at 24 weeks (12mg)~2.0% at 12mg in Phase 2 T2D trialAccurate

Importantly, Tatem adds appropriate caveats:

"There's no approved dose head-to-head readout yet in obesity, but there is a direct Phase 3 retatrutide versus tirzepatide trial that is ongoing today."

— Dr. Alex Tatem

This is a critical nuance that many content creators miss. Cross-trial comparisons (comparing Phase 2 retatrutide data to STEP 1 and SURMOUNT-1) are suggestive but not definitive — different trial populations, durations, and designs make direct comparisons imperfect. TRIUMPH-5 directly compares retatrutide with tirzepatide; its registry has no posted results at this review. Any eventual comparison will apply to that trial's population and design.

For detailed comparisons, see Retatrutide vs Mounjaro.

Side Effects: Several Denominators Need Correction

Several percentages in the video come from the whole-trial column, which includes placebo, rather than the retatrutide-treated participants alone. Table 3 of the Phase 2 paper is the relevant source.
Claim in the videoWhat the Phase 2 table shows
82% of retatrutide patients had an adverse event82% among 337 safety-evaluable participants, including placebo; active-dose groups ranged from 73% to 94%
70% with placeboCorrect: 49 of 70 placebo participants
Nausea 27%; diarrhea 13%; vomiting 10%; constipation 9%Whole-trial percentages including placebo, not active-treatment rates
Arrhythmias 6% with retatrutide versus 3% placebo6% is the whole-trial figure; the 12 mg group had 11% versus 3% with placebo
Serious adverse events 4%Reported in 4% of retatrutide-treated participants and 4% with placebo

The paper supports his description of predominantly gastrointestinal events and a dose-dependent heart-rate rise that peaked at week 24. It does not support calling the 82% figure the highest-dose rate.

Later evidence: TRIUMPH-4 reported dysesthesia in 20.9% of the 12 mg group versus 0.7% with placebo. The December 2025 announcement came after his video. Sensory symptoms were not wholly new to Phase 3: the Phase 2 paper already reported cutaneous hyperesthesia and related symptoms.
For the full safety profile, see Retatrutide Side Effects.

FDA Timeline: A Historical Forecast

Tatem discusses the approval timeline:

"The TRIUMPH study is looking to have its main obesity master protocol set for primary completion in May of 2026. This means the best case scenario for US approval is going to be 2027."

— Dr. Alex Tatem

He also mentions TRIUMPH Outcomes (cardiovascular/renal endpoints, 10,000 participants, estimated completion 2029) and the head-to-head trial against tirzepatide.

His 2027 estimate was a forecast made before the pivotal readouts. Lilly subsequently reported TRIUMPH-1 through TRIUMPH-4 results and announced a Q1 2027 BLA submission plan. No FDA approval date is confirmed. TRIUMPH-Outcomes is a separate longer-term study; its completion date is not an announced prerequisite or approval date.
For the latest timeline, see Retatrutide FDA Approval Timeline.

Grey Market Warning: Responsible

Tatem closes with a clear warning against grey market sourcing:

"We don't know what you're getting when you order these drugs from China or whatever supplier you have. Dosing can be inconsistent. And what's more concerning for me is the risk of heavy metal toxicity and other contaminants... I just cannot recommend it."

— Dr. Alex Tatem

His sourcing warning aligns with FDA's broader concerns about unapproved products, although this video does not measure contamination in any particular product. One correction to his pharmacy reference: FDA says retatrutide cannot be used in compounding under federal law. A compounding-pharmacy claim is not evidence of lawful retatrutide access.

For more on this topic, see Grey Market Retatrutide.

Frequently Asked Questions

Who is Dr. Alex Tatem?

Dr. Alex Tatem is a board-certified, fellowship-trained urologist and men's health specialist. His practice focuses on low testosterone, erectile dysfunction, Peyronie's disease, male infertility, and performance enhancement. While he is a licensed physician, his specialty is urology — not endocrinology or obesity medicine. His professional background does not remove the need to check individual claims against the original studies.

How accurate is Dr. Tatem's video?

His principal Phase 2 weight-loss numbers are correct. Several safety percentages use the whole-trial denominator, including placebo, and should not be presented as retatrutide-only rates. Human energy-expenditure claims need qualification. His September 2025 video also predates the later Phase 3 results and Lilly's current filing plan.

Does Dr. Tatem recommend retatrutide?

No. Tatem explicitly does not recommend grey market retatrutide and warns against contamination and dosing inconsistency from unregulated suppliers. He presents the clinical data objectively and states that pharmaceutical-grade retatrutide is not yet available outside of clinical trials, while discussing a possible 2027 approval. That date was his forecast, not an FDA commitment.

Is retatrutide better than semaglutide and tirzepatide?

Based on the Phase 2 data Tatem cites, retatrutide produced greater percentage weight loss (24.2% at 48 weeks) than semaglutide (14.9% at 68 weeks) or tirzepatide (20.9% at 72 weeks). However, these are cross-trial comparisons with different populations and durations — not head-to-head results. TRIUMPH-5 is designed to provide a direct comparison; its registry has no posted results at this review.

When will retatrutide be FDA approved?

No date is confirmed. His video discussed 2027 as a best case. Lilly's later July 2026 update says it plans a BLA submission in Q1 2027; submission and approval are separate milestones.

Sources

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all fact checks topics →